ISR Articles

  1. Do Strategic Partnerships Meet Outsourcers Expectations? 10/18/2021

    ISR’s CDMO Outsourcing Models report dives into three approaches to contracting manufacturing work, the motivations behind using each approach, and details on which methods earn the greatest satisfaction among users.

  2. Manufacturing Costs For Small Molecule Development Work 10/18/2021

    In Q3 2020, ISR asked 49 respondents to allocate the costs of development work and clinical trial materials for outsourced small molecule drugs. The data show that API Manufacturing and Drug Product Manufacturing and Process Development capture similar proportions of outsourced spend at this stage. 

  3. Outsourcer Engagement Preferences – No Love For Linkedin 10/1/2021

    It’s April 2020 and the world is in lockdown. You’re the chief marketing officer of a top-30 CDMO and you’re scrambling to come up with a way to pivot your marketing strategy to this new fully remote world. Most of your ideas reduce to the proverbial kitchen sink approach: throw everything online. So now, 18 months later, how well did it work?

  4. Top 5 Oral Dosage Forms By Expenditure 9/18/2021

    In Q2 2021, ISR asked 100 outsourcers of oral dose manufacturing to allocate the proportion of their company’s outsourced expenditure by dosage form. The data show that traditional tablets currently account for the largest proportion of spend, followed by controlled release tablets and immediate release tablets. However, respondents predict some of the current spend on tablets will shift to capsules five years from now. To learn more, follow the link to the Oral Dosage Forms Market Outlook report preview.

  5. Are Oral Dose Manufacturing Projects Becoming More Complicated? 9/8/2021

    Has the complexity of oral dose manufacturing projects changed in recent years? Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Data from ISR’s new report provides insight on these questions and more.

  6. Small & Emerging Outsourced Manufacturing Activities 7/6/2021

    To better understand the outsourcing practices used by respondents’ companies, ISR asked research participants to provide an estimate for various manufacturing activities.

  7. Outsourcing Drivers For Small Molecule Manufacturing 7/6/2021

    ISR’s recent survey of small molecule outsourcers found that the majority of respondents outsource for one of two reasons: for all of their manufacturing needs, or to augment their internal manufacturing capacity.

  8. Manufacturing Expenditure By Activity 7/6/2021

    We asked sponsors who outsource clinical manufacturing to identify which activities they spend the most on.

  9. Identifying The Decision-Makers At Your Customers’ Organizations 6/29/2021

    ISR was engaged by the Global Marketing Director at a Top 20 CDMO with the above question. The client had years of experience in marketing their brand to prospective customers but had recently begun to question the efficiency of their marketing spend. The client wanted to demonstrate to their company stakeholders that their marketing efforts were not only hitting the right targets, but that the language used in those efforts reflected their customers’ needs. Knowing this information would allow the client’s marketing department to move away from broad, product-based messaging focused on how good their services are, to messaging focused on how their services address their customers’ concerns.

  10. Top 5: The Pandemic’s Influence On Small Molecule API Outsourcing Risk Mitigation 6/14/2021

    In Q4 2020, ISR asked 121 outsourcers of small molecule API about how the pandemic has influenced their risk mitigation strategies with regards to outsourcing. More than half said their company has plans to increase contingency planning. One-third of respondents indicated their company plans to revisit disaster planning, to increase supply chain oversight, and to increase inventory / stock up.